Sher­lock, Feng Zhang's CRISPR di­ag­nos­tic out­fit, grabs $80M to go be­yond Covid-19

Af­ter spend­ing two years prov­ing its CRISPR and syn­thet­ic bi­ol­o­gy plat­forms could de­liv­er pow­er­ful Covid-19 di­ag­nos­tics, as well as ship­ping those test kits, Sher­lock Bio­sciences is ready to re­turn to — and tur­bocharge — its orig­i­nal mis­sion.

The Boston-based com­pa­ny has raised $80 mil­lion to de­vel­op a range of new tests that can be done on two in-house de­vices that can be used in an at-home set­ting.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER